Abstract:Background and aims: Obesity-induced chronic inflammation is a key component in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and insulin resistance. Increased secretion of proinflammatory cytokines by macrophages in metabolic tissues promotes disease progression. In the diet-induced obesity (DIO) mouse model, activation of liver resident macrophages, or Kupffer cells (KCs), drives inflammatory responses, which recruits circulating macrophages and promotes fatty liver development, and ultimately contributes to impaired hepatic insulin sensitivity. Hepatic macrophages express the highest level of vitamin D receptors (VDRs) among nonparenchymal cells, whereas VDR expression is very low in hepatocytes. VDR activation exerts anti-inflammatory effects in immune cells. Approach and results: Here we found that VDR activation exhibits strong anti-inflammatory effects in mouse hepatic macrophages, including those isolated from DIO livers, and mice with genetic loss of Vdr developed spontaneous hepatic inflammation at 6 months of age. Under the chronic inflammation conditions of the DIO model, VDR activation by the vitamin D analog calcipotriol reduced liver inflammation and hepatic steatosis, significantly improving insulin sensitivity. The hyperinsulinemic euglycemic clamp revealed that VDR activation greatly increased the glucose infusion rate, while hepatic glucose production was remarkably decreased. Glucose uptake in muscle and adipose did not show similar effects, suggesting that improved hepatic insulin sensitivity is the primary contributor to the beneficial effects of VDR activation. Finally, specifically ablating liver macrophages by treatment with clodronate liposomes largely abolished the beneficial metabolic effects of calcipotriol, confirming that VDR activation in liver macrophages is required for the antidiabetic effect. Conclusions: Activation of liver macrophage VDRs by vitamin D ligands ameliorates liver inflammation, steatosis and insulin resistance. Our results suggest therapeutic paradigms for treatment of NAFLD and type 2 diabetes mellitus.

Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Vitamin D Receptor Targets Hepatocyte Nuclear Factor 4α and Mediates Protective Effects of Vitamin D in Nonalcoholic Fatty Liver Disease.

Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease

Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease

Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway

Gene Polymorphisms and Biological Effects of Vitamin D Receptor on Nonalcoholic Fatty Liver Disease Development and Progression

Vitamin D–VDR Novel Anti-Inflammatory Molecules—New Insights into Their Effects on Liver Diseases

The Association Between Serum Vitamin D Level and Nonalcoholic Fatty Liver Disease

Vitamin D alleviates non-alcoholic fatty liver disease via restoring gut microbiota and metabolism

Meta-analysis: vitamin D and non-alcoholic fatty liver disease

Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update

Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?

Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis

Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment

Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice

Vitamin D 1,25-Dihydroxyvitamin D 3 reduces lipid accumulation in hepatocytes by inhibiting M1 macrophage polarization

Vitamin D Levels in Non-alcoholic Fatty Liver Disease in Type II Diabetic and Non-Diabetic Patients

Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease